pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 1·1 min read
save

WuXi AppTec seeks court order to remove itself from U.S. Pentagon's Chinese military-linked company list

Jul 1, 2026·read at Endpoints ↗RegulatoryNeutral

WuXi AppTec has filed a petition for a preliminary injunction to halt its inclusion on the Pentagon's list of firms with alleged ties to the Chinese military.

The company says the designation is damaging its business, noting that several customers have suspended relationships as a result.

The injunction, dated June 29, seeks to suspend the impact of the listing while the case proceeds.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “WuXi AppTec seeks injunction over China military list”

read at Endpoints ↗
83 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoHealth tech investors are looking at bigger betsEndpoints
  • 3h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 4h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 4h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints
  • 13h agoUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsEndpoints